ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Judge Partially Denies Bayer’s Bid to Dismiss 12 Essure Cases


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Judge holding gavel in courtroom

A judge has partially denied Bayer’s motion to dismiss the cases of 12 women who say the Essure birth control device injured them, according to court records.

Bayer argued that the statute of limitations had passed on all 12 cases, and therefore, the judge should rule in its favor and grant partial summary judgement and dismiss them.

On March 27, 2019, Judge John R. Padova dismissed three of the 12 cases but allowed the others to continue on some claims.

Plaintiffs’ attorneys are calling the judge’s decision an important win for current and future Essure lawsuits against Bayer.

“I think going forward we've got a great road map to continue to show the court — if we have to — that all these cases are all going to get past the statute of limitations defense.”

Justin Parafinczuk, plaintiff’s attorney

“We’re very happy with the way the judge handled the claims and went through these very fact intensive issues,” plaintiff’s attorney Justin Parafinczuk told Drugwatch. “I think going forward we’ve got a great road map to continue to show the court — if we have to — that all these cases are all going to get past the statute of limitations defense.”

Doctors implant the Essure device in the fallopian tubes where it creates scar tissue to block sperm from reaching eggs. But in the past several years, thousands of women say the device has caused complications and some women have died.

Bayer discontinued the device in December 2018 because of poor sales, according to past statements. But thousands of lawsuits remain.

Essure Litigation ‘More Complicated’

The Essure litigation has been one of the more complicated mass tort litigations. The vocal nature of plaintiffs has also set this tort apart from others.

“It’s more complicated on the preemption issue, and the statute of limitations issues are complicated,” Parafinczuk said. “And then I think it’s different in that you have plaintiffs that are very active on a national level and on social media and are confronting Bayer about this. That’s not something you see in a lot of these cases.”

Related Patient Story

The U.S. District Court for the Eastern District of Pennsylvania held argument for Bayer’s motion for partial summary judgement on Feb. 11, 2019. The judge based his decision on several key facts of each case, according to a March 27, 2019 memorandum.

The judge considered:

  • Statute of limitations — whether time had run out on each case
  • Discovery rule — an exception to the statute of limitations for tort claims that applies in certain cases
  • Breach of warranty — refers to a company’s failure to live up to a claim made about a product
  • Fraudulent concealment — when a company hides a fact that it had a duty to disclose

While the judge did rule in Bayer’s favor in three of the cases and dismissed them, the remaining cases will proceed on a few different claims.

Bayer Will ‘Vigorously Defend’ Against Remaining Cases

Bayer is also happy with the ruling, the pharmaceutical giant said in a statement obtained by The Pennsylvania Record. The company vows to “vigorously defend itself” against these cases.

“Bayer is pleased with the Court’s ruling that many of the plaintiffs’ claims were time-barred by the statute of limitations, and with its implication for hundreds of other claims in this litigation,” spokesperson Christopher Loder said in the statement.

In July 2018, Bayer spokesperson Courtney Mallon told Drugwatch a total of 52 complaints in the Essure litigation had been dismissed or significantly narrowed. Since then, Loder said the number of dismissed or narrowed complaints has increased to 57.

But thousands more lawsuits are pending. As of Jan. 28, 2019, Bayer faced 29,400 lawsuits in the United States, according to the company’s 2018 annual report.

“[Bayer] has continually said they are going to get the majority of these cases dismissed, and that's clearly not happening.”

Justin Parafinczuk, plaintiff’s attorney

“The important thing is that [these cases] were selected by the defense, and they were only able to successfully get rid of three of them — out of 12 — and only one of our cases,” Parafinczuk said. “[Bayer] has continually said they are going to get the majority of these cases dismissed, and that’s clearly not happening.”

Parafinczuk said people who are looking to file lawsuits should be mindful of the statute of limitations and consult a lawyer to protect their rights.

Michelle Llamas, Senior Content Writer
Written By Michelle Llamas Senior Writer

Michelle Llamas has been writing articles and producing podcasts about drugs, medical devices and the FDA for nearly a decade. She focuses on various medical conditions, health policy, COVID-19, LGBTQ health, mental health and women’s health issues. Michelle collaborates with experts, including board-certified doctors, patients and advocates, to provide trusted health information to the public. Some of her qualifications include:

  • Member of American Medical Writers Association (AMWA) and former Engage Committee and Membership Committee member
  • Centers for Disease Control and Prevention (CDC) Health Literacy certificates
  • Original works published or cited in The Lancet, British Journal of Clinical Pharmacology and the Journal for Palliative Medicine
Edited By
Emily Miller
Emily Miller Managing Editor

3 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Bayer. (2019). 2018 Annual Report. Retrieved from
  2. Malfitano, N. (2019, April 2). Essure plaintiffs barred from suing Bayer because they missed their timeframe. Retrieved from
  3. McLaughlin v. Bayer. (2019, March 27). In The United States District Court For The Eastern District Of Pennsylvania. Memorandum. Retrieved from,_CORP_et_al
View All Sources
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617